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In humans, a number of genetic factors have been linked to the development of fibrosis in a variety of different
organs. Seeking a wider understanding of this observation in man is ethically important. There is mounting
evidence suggesting that inbred mouse strains with different genetic backgrounds demonstrate variable
susceptibility to a fibrotic injury. We performed a systematic review of the literature describing strain and organ
specific response to injury in order to determine whether genetic susceptibility plays a role in fibrogenesis. Data
were collected from studies that were deemed eligible for analysis based on set inclusion criteria, and findings
were assessed in relation to strain of mouse, type of injury and organ of investigation. A total of 44 studies were
included covering 21 mouse strains and focusing on fibrosis in the lung, liver, kidney, intestine and heart. There is
evidence that mouse strain differences influence susceptibility to fibrosis and this appears to be organ specific. For
instance, C57BL/6J mice are resistant to hepatic, renal and cardiac fibrosis but susceptible to pulmonary and
intestinal fibrosis. However, BALB/c mice are resistant to pulmonary fibrosis but susceptible to hepatic fibrosis. Few
studies have assessed the effect of the same injury stimulus in different organ systems using the same strains of
mouse. Such mouse strain studies may prove useful in elucidating the genetic as well as epigenetic factors in
humans that could help determine why some people are more susceptible to the development of certain organ
specific fibrosis than others.
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Genetic susceptibility is thought to be an important risk
factor for many diseases [1]. Many conditions do not ap-
pear to be induced entirely by environmental factors and
so genetic profiles have been studied to determine why
some individuals are more susceptible to particular dis-
eases. Whole-genome studies have provided a useful
insight into how gene patterns may influence the develop-
ment and/or progression of certain pathological pathways,
including fibrosis [2]. This pathological end stage of tissue
repair is characterised by excess extracellular matrix
(ECM) deposition due to increased production and/or an
imbalance in turnover often resulting in functional dam-
age in tissues and organs [3,4]. Animal models have shown* Correspondence: louise.walkin-2@postgrad.manchester.ac.uk
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reproduction in any medium, provided the orthat the fibrotic response to various injurious agents dif-
fers as a result of genetic background [5,6]. In particular,
different strains of rodents vary in their susceptibility to
scarring and fibrotic pathologies and evidence suggests
that such strain susceptibility may be organ specific [7,8].
The majority of genomic studies used to identify sus-
ceptibility pathways involved in disease pathologies have
been performed in the mouse. Mice provide a suitable
model for the study of human genetics because more
than 95% of the genome is identical. Mice are also easy
to breed with a short generation time and a short life
span allowing direct study of disease development and
can accurately eludicidate how genetic sequences may
vary in different strains and result in susceptibility to fi-
brotic pathologies. Quantitative trait locus (QTL) ana-
lysis is a common genetic approach that has been used
in the past two decades to identify loci involved in dif-
ferences in fibrotic response between inbred strains of
mice [9]. In this approach, two inbred strains that differ inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ther mated together (intercross) or to one of the parental
strains (backcross). The resulting second generation is
phenotyped and genotyped for DNA markers covering the
genome so that linkage analysis can be performed and loci
identified. To date, the Mouse Genome Database through
The Jackson Laboratory, lists 24 QTL in mice associated
with fibrosis of which all but 3 are phenotypes in the lung.
These QTL span large genetic regions often containing
hundreds of genes and identifying the causal gene has
been a major challenge. However, new genetic approaches
like genome-wide association mapping [10] and the use of
Collaborative Cross [11] and Diversity Outbred [12] mice
all provide higher mapping resolution that should improve
identification. Quantitative trait loci analysis can be time
consuming and can only analyse two different mouse
strains at a time. Alternatively, haplotype association map-
ping (HAM) is a phenotype-driven approach that requires
genotyping to be performed only once and is able to
achieve a higher resolution compared with other ap-
proaches [13].
The mouse genome is easy to manipulate to allow dis-
eases to be modelled in transgenic animals when the
‘causative’ genes have been determined [14]. In the
current study, we summarise the evidence from murine
studies performed to assess fibrosis in different organs,
and we discuss the influence of mouse strain on the sus-
ceptibility to fibrosis in these organs.
Overview of fibrosis
Tissue repair is a normal response to injury and involves
an orchestrated series of events with the end stage being
extracellular matrix (ECM) remodelling leading to scar-
ring/fibrosis [15]. Initial haemostasis and inflammation
events are followed by granulation tissue formation with
the influx and proliferation of fibroblasts and angiogenesis,
restoration of epithelial integrity and subsequent ECM de-
position and remodelling with apoptosis of myofibroblasts
as part of the resolution phase [16,17]. Fibrosis usually de-
velops in response to repeated injury and chronic inflam-
mation and is characterised by excess deposition and
accumulation of ECM components often leading to a loss
in tissue function. The development of a fibrotic phenotype
is generally thought to follow the same pathways as wound
healing but due to changes in the cellular and molecular
mechanisms and defective resolution of repair events the
response becomes extended and often irreversible [18].
Characteristic fibrotic features often include epithelial cell
hyperplasia, accumulation of inflammatory cells, and per-
sistence of myofibroblasts with the extensive deposition of
excess ECM components. The presence of inflammatory
cells and production of a multitude of growth factors and
cytokines drives and exacerbates the synthesis of ECM. In
combination, reduced degradation and turnover due to animbalance of matrix metalloproteinases (MMPs) with tis-
sue inhibitors of metalloproteinases (TIMPS), results in a
net matrix accumulation. Although a number of fibrotic
mediators have been identified, transforming growth
factor-β (TGF-β) plays a central role in ECM deposition
and subsequent remodelling events and remains a key
therapeutic target [19].
The development of many types of organ fibrosis has
been investigated using mouse models however there are
clear differences in the severity of the response to injuri-
ous agents between various strains of mice (Table 1). It is
also apparent that particular strains may be susceptible to
fibrosis in one organ but resistant to fibrosis in other or-
gans. It is therefore possible that susceptibility to fibrosis
may not just be strain specific but also organ specific. We
have performed a systematic review to determine the val-
idity and inform on the appropriateness of using a particu-
lar mouse strain to model a human organ-specific fibrotic
pathology. Such information may also be beneficial in de-
termining which genetic signatures are associated with
susceptibility to fibrosis and have translational relevance
to identify individuals who may be susceptible to the de-
velopment of a fibrotic phenotype in a particular organ
following injury or disease.
Systematic review of mouse strain differences in the
susceptibility to fibrosis in different organs
Searches were performed online using MEDLINE from
1980 to July 2013 limited by ‘animals’ and routinely using
two sets of keywords ‘fibrosis AND genetics’ and ‘fibrosis
AND strain’ with a third set of keywords as follows: lung
OR pulmonary; hepatic OR liver, renal OR kidney; intes-
tinal OR bowel; and cardiac OR heart. Studies were con-
sidered eligible for analysis if they (1) compared at least
two different strains of mice, (2) quantified a fibrotic indi-
cator in a particular organ(s) as an outcome measure, and
(3) used a particular type of injurious agent. From the 44
studies found to fit the criteria, a total of 22 were analysed
for pulmonary fibrosis, 8 for hepatic fibrosis, 6 for renal fi-
brosis, 3 for intestinal fibrosis and 5 for cardiac fibrosis.
Mouse strain differences in susceptibility to
pulmonary fibrosis
Pulmonary fibrosis (PF) is a complex disease with excessive
deposition of collagen and other ECM components in the
pulmonary interstitium preventing normal gaseous ex-
change [35,36]. The disease has an incidence of appro-
ximately 7 to 10 in 100,000 people with a high mortality 2
to 5 years after diagnosis [36,37]. Inflammatory, apoptotic
and remodelling (MMPs/TIMPs) events have all been im-
plicated in pathogenesis [38-40]. Idiopathic pulmonary fib-
rosis, the most common form, has an unknown aetiology.
It is recognised that bleomycin, a chemotherapeutic agent
used clinically in cancer patients, causes some patients to
Table 1 Summary of the various types of organ fibrosis
and associated mouse strain susceptibility
Strain Susceptibility Fibrosis type Reference
















BALB/cJ Susceptible Hepatic [20]
C3Hf/Kam Resistant Pulmonary [30]
Intestinal [23,24]
C3H/HeJ Intermediate Hepatic [20]
A/J Susceptible Cardiac [29]
Resistant Hepatic [20]
Pulmonary [31]
DBA/2 Intermediate Pulmonary [22]
DBA/2J Intermediate Hepatic [20]
MRL/MpJ Resistant Renal [32]
Cardiac [33]
Susceptible Cardiac [34]
MRL/MpJlpr/lpr Susceptible Renal [32]
129S1/SvJM Susceptible Renal [8]
129Sv Resistant Renal [27]
129S3 Susceptible Renal [28]
Swiss Intermediate Pulmonary [22]
AKR/J Resistant Hepatic [20]
CD1 Susceptible Renal [27]
[28]
FVB/NJ Resistant Hepatic [20]
Col4A3-/- Susceptible Renal [32]
Walkin et al. Fibrogenesis & Tissue Repair 2013, 6:18 Page 3 of 12
http://www.fibrogenesis.com/content/6/1/18develop PF as a side effect [40,41]. Pulmonary fibrosis pa-
tients demonstrate a large amount of symptomatic vari-
ability, which has encouraged the exploration of possible
genetic influences [42].
Intra-tracheal delivery of bleomycin in rodents causes
lung damage through direct DNA strand breakage and
generation of free radicals inducing oxidative stress [43].Radiation is another known causative agent, and this has
also been used in some animal models of pulmonary fibro-
sis. Using the search terms described, 22 studies fitted the
criteria with bleomycin and radiation as injurious agents,
12 used bleomycin as the injurious agent and 10 used radi-
ation as the injurious agent. Results suggest that different
mouse strains were either susceptible or resistant to
bleomycin-induced lung fibrosis. However, the dose of
bleomycin, number of applications, as well as the route of
administration, was not standardised, which may impact
on the extent of the fibrotic response in different studies.
In one study, a single intra-tracheal dose of bleomycin
was used and the fibrotic response determined by assessing
collagen synthesis and deposition. C57BL/6 mice were
most susceptible, DBA/2 and Swiss mice were intermediate
whereas BALB/c were most resistant to lung fibrosis [22].
In another study, mRNA expression of a panel of cytokines
linked to fibrosis was assessed after a single dose of bleo-
mycin in two mouse strains, C57BL/6J and BALB/cBy [44].
TGF-β1 gene expression was found to be threefold lower
in resistant BALB/cBy mice in comparison to a sevenfold
increase in susceptible C57BL/6J mice. In addition, BALB/
cBy mice were found to have fourfold higher levels of IL-
1β mRNA than C57BL/6J mice suggesting a possible pro-
tective effect of IL-1β. However, no strain difference was
found with TGF-β2, IFN-γ, IL-2, IL-3 or IL-4 mRNA levels
but gene expression for IL-4 receptor was higher in
C57BL/6J suggesting this receptor may play a role in the
susceptibility to pulmonary fibrosis.
Strain differences between C57BL/6 and BALB/c mice
were also confirmed in another study following a single
intra-tracheal dose of bleomycin as collagen deposition
was higher in C57BL/6 mouse lungs compared with
BALB/c lungs at 16 days and had increased further at
30 days after administration. Connective tissue growth
factor (CTGF), a downstream mediator of TGF-β, was
also found to be upregulated in C57BL/6 mice but not
in the BALB/c strain [45]. The strain difference may be
due to a reduced production of bleomycin hydrolase ac-
tivity resulting in limited oxygen free radical induction
in the lungs of BALB/c mice [46]. Another possibility to
explain the strain differences in response to bleomycin
may be less DNA breakage in BALB/c lungs [47].
In a separate study, after a single intra-tracheal injec-
tion of the bleomycin, C57BL/6 mice showed increased
expression for MMP-2, MMP-7, MMP-9 and MMP-13
at both 7 and 14 days after administration compared
with the BALB/c strain. TIMP-1, an endogenous inhibi-
tor of MMPs, was upregulated in the lungs of C57BL/6
mice but not in BALB/c mice. Experimental reduction
of MMP expression did not, however, alleviate fibrosis
in C57BL/6 mice and there was no change in TIMP-1
levels, which led to the conclusion that although expres-
sion varies between the strains, TIMP-1 overexpression
Walkin et al. Fibrogenesis & Tissue Repair 2013, 6:18 Page 4 of 12
http://www.fibrogenesis.com/content/6/1/18does not obviously alter the development of lung dis-
ease in mice [48].
Another group also identified BALB/c mice as being
fibrosis resistant and C57BL/6 mice as being fibrosis
susceptible following adenovirus delivery of active TGF-
β1 [39]. In a subsequent study, the same group showed
that adenoviral lung delivery of the downstream medi-
ator of TGF-β1, connective tissue growth factor (CTGF)
in combination with a single intra-tracheal injection of
bleomycin caused BALB/c mice to develop a fibrotic
phenotype similar to that of the C57BL/6 strain with a
persistent upregulation of TIMP-1 [49].
Although the exact mechanism underlying the differ-
ence in fibrotic response between these two strains of
mice is unclear, a number of other theories have been
proposed, including a reduced production of bleomycin
hydrolase activity as mentioned earlier [46]. Furthermore,
there is reduced poly(ADP-ribose) polymerase activity
and, hence, less DNA breakage in BALB/c lungs compared
with C57BL/6 mice after bleomycin exposure [47,50].
A further study investigated the effect of mouse strain
variation on the expression of genes associated with apop-
tosis in bleomycin-induced pulmonary fibrosis. A single
dose of bleomycin was administered to the trachea of two
strains of mice, NMRI and C57BL/6, and expression of
BAX, an apoptotic gene that down-regulates BCL-2, a
death repressor gene, was analysed in lung tissue as was
collagen content. After 14 days, although the fibrotic re-
sponse appeared similar in both strains, BCL-2 was
upregulated in myofibroblasts of NMRI mouse lungs but
not in C57BL/6. BAX was upregulated in alveolar epithe-
lial cells of both strains but was only downregulated in
myofibroblasts of C57BL/6 lungs, suggesting that the
regulation of apoptotic genes may be specific to cell type
in the different strains of mice [51].
A later study used both a single dose and a repetitive
exposure to bleomycin with a three-time weekly injec-
tion by intra-tracheal administration to encourage a
chronic response in C57BL/6J mice and DBA/2 mice
[52]. Collagen content of the lung at 3 and 6 weeks after
the last injection was measured as a fibrotic readout.
Interestingly, bleomycin administration induced a Th2
response in both the Th-1 biased C57BL/6J mice and
Th-2 biased DBA/2 mice. Fibrotic changes were evident
in both strains at early time points but were prolonged
only after repeated exposures in DBA/2 mice. However,
when the repair process was experimentally delayed in
C57BL/6J mice, these mice also showed prolonged fibro-
sis after multiple bleomycin exposures, leading to the
conclusion that genetic background and type of injury
are both relevant in the persistence of lung fibrosis [52].
Haston and colleagues used a subcutaneous osmotic
mini-pump to deliver bleomycin to the lungs of C57BL/
6J and C3Hf/Kam mice as an alternative to repeatedinjection [7]. The fibrotic phenotype was measured by
assessing collagen deposition in the lungs by histological
assessment up to 8 weeks after treatment. Examining
the offspring in the F1 and F2 generations after inter-
crossing between strains showed that mice with a strong
C57BL/6J background developed substantial fibrosis,
which was more obvious in male mice whilst mice with
the C3Hf/Kam background did not show a response [7].
In a follow-up study, the same group went on to map
loci linked to the phenotypic difference in the response to
bleomycin between the two mouse strains and found two
regions named: Blmpf1, the MHC complex on chromo-
some 17, and Blmpf2 on chromosome 11 in males only
[30]. Using linkage analysis, the group showed that inherit-
ance of B6 alleles at either locus increased the fibrosis
phenotype of B6 x C3H cross F2 mice. In a follow-up
study, loci regulating bleomycin-induced lung fibrosis were
mapped in fibrosis-prone C57BL/6J mice compared with
the fibrosis-resistant A/J strain [31]. Genetic analysis found
3,304 genes that were differentially expressed between the
two strains, with 246 linked to susceptibility to lung fibro-
sis and many of these linked to heparin binding and ECM
deposition pathways [31]. Additional gene expression and
sequencing studies using a fibrosis-prone C57BL/6J and
fibrosis-resistant C3Hf/KAM mouse cross examined sus-
ceptibility genes linked with bleomycin-induced pulmonary
fibrosis [53]. Results showed that 1,862 genes or expressed
sequence tags (ESTs) were differentially expressed between
treated C57BL/6J and C3Hf/KAM mice, and 67 of these
mapped to Blmpf1 or 2. This group of genetic elements in-
cludes genes relating to apoptosis, immune regulation and
oxidative stress. Assessing the correlation among other in-
bred strains showed that 36% of the sequence variations
between these strains can predict for the well-known
bleomycin-induced pulmonary fibrosis susceptibility of
the DBA mice and the resistance of the A/J mice [53]. In
vitro studies have reported the same pattern of strain spe-
cific response in cultured cells. For instance, the response
of specific mouse strain-derived lung fibroblasts to asbes-
tos rather than bleomycin as the injurious agent showed
that lung fibroblasts from the 129 mouse strain prolifer-
ated less than those from the C57BL/6 and SJL strain and
showed a reduced response in terms of cell proliferation
to PDGF [54].
Radiation therapy in the thoracic cavity produces a
similar fibrotic lung phenotype to bleomycin treatment.
Damage to lung tissue by radiation may produce an in-
flammatory pneumonitis reaction or chronic fibrosis
with ECM accumulation. Several groups have shown dif-
ferences in the development of pulmonary fibrosis fol-
lowing radiation damage using different mouse strains.
In response to a single dose of radiation to the thorax,
C57BL/6 mice were shown to be more prone to pulmon-
ary fibrosis and C3H/HeJ and CBA/J mice more resistant
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C57BL/6 mice and C3H/HeJ mice exposed to two doses
of radiation to the thorax and measured gene expres-
sion of collagen I, III and IV, fibronectin, and TGF-β1
and TGF-β3 at 8, 16 and 26 weeks. Expression was
shown to be unaltered in the resistant C3H/HeJ strain
until 26 weeks after radiation, whereas with the C57BL/
6 mice, increased levels of collagen I and fibronectin
were seen in the lungs at all time points [56]. In a fur-
ther study by the same group, IL-1 alpha and TNF-
alpha were proposed to play a role in susceptibility to
radiation induced pulmonary fibrosis however IL-1
beta may have a protective role [57].
Iwakawa and colleagues investigated the effect of two
doses of radiation on two strains of mice (C57BL/6
J and C3H/HeMs) and histological analysis demon-
strated that C3H/HeMs mice are able to clear ECM
more rapidly after radiation-induced inflammation
compared to C57BL/6J [58]. Gene-expression analysis
suggested that Ltf, Ifi202a, Ill8, Per3, Mmp12, Cap1
and Rad51ap1 are linked with mouse strain differences
in the fibrotic response to radiation. Ao and colleagues
also analysed the difference in cytokine expression after
radiation damage in fibrosis-sensitive (C57BL/6) and
resistant (C3H) mice. An increase in cytokine levels
occurred earlier in the C57BL/6 mice and was also
more enhanced supporting the fibrotic phenotype [59].
A further study assessed the lung fibrotic responses of
C57BL/6 mice to three doses of radiation comparing
C57/L and CBA mouse strains. The most significant
finding was the difference between the two different
C57 strains, as C57/L mice were more sensitive and de-
veloped early pneumonitis and fibrosis at 3 to 4 months
while C57BL/6 mice presented with a delayed response
at 6 to 9 months [60]. This finding was also confirmed
in another study suggesting that the C57/L strain is a
better fibrotic sensitive strain than the CBA strain to
use in radiation studies [61]. Following whole-body ra-
diation, C57BL/6J mice were more susceptible to fibrosis
and displayed higher TGF-β1 mRNA on day 9 compared
to C3H/J. There was no TGF-β1 gene expression produc-
tion in controls or in both groups by day 56 [62].
Haston’s group administered two doses of radiation in
two strains of mice, sensitive C57BL/6J and resistant
C3Hf/Kam, and in their intercross F1 and F2 offspring,
and data suggested that approximately 38% of the
phenotypic differences were linked to a few genetic fac-
tors [63]. Using phenotypic data, a genome-wide linkage
scan found evidence for a quantitative trait locus (QTL)
on chromosome 17, which appeared to influence sus-
ceptibility to radiation-induced pulmonary fibrosis simi-
lar to that found with bleomycin induced fibrosis. This
suggests that that area of chromosome 17 may contain
a lung injury gene [30].The identification of fibrosis genes in humans has been
extensively studied, and a number of polymorphisms relat-
ing to susceptibility to idiopathic pulmonary fibrosis have
been found. However, despite the developments in mouse
strain studies, there have not yet been any QTLs found in
the humans to help determine those at risk of developing
lung fibrosis. More study into the mouse genome and po-
tential candidate genes will eventually allow study in the
human condition into the same candidate genes to estab-
lish susceptibility to lung fibrosis.
Mouse strain differences in susceptibility to hepatic fibrosis
Chronic liver disease, such as cirrhosis and hepatitis, re-
sults in the development of liver fibrosis and is a leading
cause of death [64]. All chronic injuries to the liver,
whether viral, immune, metabolic, obstructive or toxic,
lead to fibrosis regardless of the injurious agent or the
route of injury [65]. When injury occurs, a heterogenous
population of hepatic myofibroblasts are primarily re-
sponsible for the fibrotic response [66]. Myofibroblasts
come from a number of possible sources including acti-
vation of mesenchymal cells such as fibroblasts and hep-
atic stellate cells, via EMT from epithelial cells or by
recruitment from the bone narrow. With an increase in
ECM deposition, normal liver tissue becomes replaced
by scar tissue with changes in the organisational struc-
ture that can lead to organ failure.
The most common experimental model uses mice to
study hepatic fibrosis induced by diet changes or ad-
ministrations of carbon tetrachloride (CCl4), which is a
hepatotoxin and causes hepatocyte death and liver de-
generation [67]. Using the search terms described, eight
studies fitted the criteria with carbon tetrachloride used
in two studies and a specific diet used to induce fibrosis
in six studies.
From these studies, there was substantial evidence to
suggest that certain mouse strains were either suscep-
tible or resistant to hepatic fibrosis. In particular, BALB/
c mice were fibrosis-susceptible which is in contrast to
findings for lung fibrosis [21]. BALB/c mice were found
to be susceptible to fibrosis induced by CCl4 whereas
C57BL/6J mice were fibrosis-resistant. Interestingly, even
though BALB/c mice were found to be susceptible to fi-
brosis induced by CCl4 they were resistant to fibrosis in-
duced by a carcinogenic diet. Such findings suggest that
the route and type of injury and the subsequent pathways
activated are linked to susceptibility. As with mouse lung
fibrosis studies, the dose of injurious agent (CCl4), the
number of administrations, and the route of administra-
tion was found to vary in the different studies making a
determination of impact of the various agents on the ex-
tent of the liver fibrosis difficult.
Shi and colleagues induced liver injury in two mouse
strains by four gavage administrations of CCl4 at 7-day
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the final dose was administered [21]. In contrast to lung
fibrosis findings, BALB/c mice showed severe liver fibro-
sis at day 7 whereas the C57BL/6 mice developed min-
imal fibrosis with reduced ECM expression and lower
levels of pro-collagen I mRNA detected [21]. Further-
more, BALB/c mice showed a Th2 response whereas
C57BL/6 mice showed a Th1 response and the authors
propose a role for immune modulation in liver fibrosis
and that the T cell cytokine profile may regulate the fi-
brotic response to injury.
A wider examination of strain differences used a proto-
col involving two intraperitoneal (IP) CCl4 injections per
week, for either 6 or 10 weeks and the fibrotic response
was assessed 2 days after the last dose in seven strains of
mice: A/J, AKR/J, BALB/cJ, C57BL/6J, C3H/HeJ, DBA/2J
and FVB/NJ [20]. BALB/cJ mice were again the most sus-
ceptible strain with significantly higher levels of liver hy-
droxyproline as a measure of collagen compared to AKR/
J, A/J and FVB/N mice. C57BL/6J mice developed an
intermediate response; however, Shi et al. [21] showed that
C57BL/6J mice are resistant to CCl4 induced fibrosis,
suggesting that the route of injury or administration re-
gime may affect the fibrotic response Further QTL ana-
lysis of intercross F1 progeny found that liver fibrosis was
linked to a susceptibility locus on chromosome 15 known
as hepatic fibrogenic gene 1 (hfib1) [20].
A carcinogenic diet was used in a second model of liver
injury to compare the fibrotic response between BALB/c
and C57BL/6 mice [25]. The choline-deficient, ethionine-
supplemented diet induced oval cell proliferation to mimic
liver injury. Oval cells are essentially the ‘stem cells’ of the
liver that can transform into any of the many cell types
found in the liver [68]. Mice were fed a choline-deficient
chow and ethionine-supplemented water, and the fibrotic
response in the liver was measured over 21 days. In this
study, BALB/c mice showed a reduced response compared
with C57BL/6 mice suggesting that the livers of mice with
a genetic background similar to C57BL/6 may be more
susceptible to a fibrotic response [25]. The contradicting
results between the two models could be explained by the
fact that the two models induce different types of liver in-
jury and BALB/c mice may be susceptible to one injurious
pathway but protected from another. There may be cer-
tain pathways that are activated in response to a specific
injury, causing particular strains to be susceptible to one
type of injury but less susceptible to another.
Millward and colleagues had shown previously that
there were QTLs in the chromosome substitution strain
(CSS)-17 mouse strain that made it resistant to obesity
and liver steatosis whilst on a high fat diet [69]. These
were QTL 13 (Orbq13) and QTL 15 (Orbq15) A later
study by the group compared the CCS-17 strain to
C57BL/6 and A/J mice and used a diet induced or CCl4injury. In comparing these strains they determined that
Orbq13 led to resistance to liver injury and Orbq15 led
to susceptibility to liver injury. C57BL/6 and A/J strains
sequencing data showed that the Orbq genes contained
small nucleotide polymorphisms within the gene. They
were able to identify candidate genes that modulate gen-
etic susceptibility to alcoholic steatohepatitis [70].
Another study assessed the effect of a methionine-
choline deficient diet on seven inbred strains; A/J, AKR/J,
BALB/c, C57BL/6J, DBA/2J, C3H/HeJ and 129x1/SvJWT.
A/J mice demonstrated the highest steatohepatitis and
gene loci were identified on four chromosomes, particu-
larly chromosomes 2 and 15 in regions that had previously
been identified for liver fibrosis [71]. Other studies have
assessed the susceptibility between two strains - C57BL/
6 N and C3H/HeN - using the same model of a
methionine-choline deficient diet. C57BL/6 N livers were
shown to have the highest inflammation, steatosis and
lipid contents and a higher degree of fibrosis, showing that
this strain is more susceptible to diet-induced liver fibrosis
[72]. Another study used a methyl-deficient diet and com-
pared C57BL/6J and DBA/2J mice. DBA/2J demonstrated
more severe changes and had a greater extent of fibrosis
genes in their livers. There were also changes in miRNA
and the protein levels of their targets [73].
Genome-wide association studies (GWAS) assess the
association between genetic variants across the whole
genome and a known disease of interest. Several have
been performed in patients with hepatic disease with
particular genes being determined as risk genes. In terms
of hepatic fibrosis, seven genes have been identified as
being risk genes with single nucleotide polymorphisms
(SNPs) also being identified [74]. The combination of
these investigations with inbred mouse genomic analysis
studies may determine susceptibility to hepatic disease
in humans.
Mouse strain differences in susceptibility to renal fibrosis
Diabetic nephropathy and chronic kidney disease (CKD)
are two leading causes of end stage renal disease (ESRD).
They both involve the progressive loss of kidney function
leading to renal failure and eventual death. CKD is mainly
caused by diabetes and hypertension and characterised by
reduced glomerular filtration rate (GFR) proteinuria, inter-
stitial fibrosis and anaemia [26]. Diabetic nephropathy has
similar features with reduced renal function and an in-
creased risk of cardiovascular disease. Histological features
include glomerular hypertrophy, thickening of the glom-
erular basement membrane, matrix expansion and inter-
stitial fibrosis. Renal fibrosis is implicated in both of these
conditions and is characterised by glomerular injury, tubu-
lar atrophy and tubule-interstitial fibrosis, which manifests
clinically as proteinuria, which can progress to end stage
renal disease (ESRD) [26].
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unilateral ureteral obstruction (UUO), which mimics the
effects of diabetes and CKD [75]. Other models include
using IP injection of bovine serum albumin (BSA), which
increases the amount of protein in the urine and induces
fibrosis. Another method involves inducing diabetes to
cause renal injury and eventual fibrosis. Using the search
terms described, six studies fitted the criteria with unilat-
eral ureteral obstruction used in two studies, IP injection
of BSA used in one study, induction of diabetes used in
one study, IP injection of recombinant human bone mor-
phogenetic protein (rhBMP) used in one study and induc-
tion of hypertension used in one study. From these studies,
there was substantial evidence to suggest that certain
mouse strains were either susceptible or resistant to renal
fibrosis. However, the only strain that was examined in two
different models was the C57BL/6 mouse, which was
found to be resistant to fibrosis in both the diabetes in-
duced and BSA administration studies [27]. However, as
with pulmonary and hepatic fibrosis studies, the route of
administration was found to vary greatly between models
and was likely to impact the extent of fibrosis. It is possible
that susceptibility to fibrosis is linked to the type of injury
induced and may affect the patterns seen between the
strains. The fibrotic response in the kidney to IP injections
of bovine serum albumin (BSA) at 10 mg per gram of body
weight for 6 weeks was measured in two strains of mice.
129S1/svImJ mice were found to be susceptible to renal fi-
brosis and C57BL/6 mice were found to be resistant [8].
However, a previous study reported that both these
strains were resistant to fibrosis induced by diabetic ne-
phropathy, with outbred CD1 mice being more suscep-
tible to renal fibrosis [27]. Diabetes was induced by a
single IP injection of streptozotocin at 200 mg/kg and
mice were sacrificed at 3.5 months and 6 months. It is
possible that the time frame in which the fibrotic re-
sponse was measured, as well as the route of injury,
may have affected the outcome. It also suggests that
there may be a grading in the response between strains.
Susceptibility to chronic kidney disease (CKD) also dem-
onstrates mouse strain differences in fibrotic response.
Chronic renal injury can be induced in mice by clamping
the renal arteries, UUO or folic acid administration [28].
Interstitial fibrosis and glomerulosclerosis developed in
both CD1 and 129S3 mice after 12 weeks. However,
C57BL/6 mice, at 16 weeks, did not develop these symp-
toms. Pharmacological manipulation of blood pressure
with angiotensin II affected susceptibility as C567BL/6
mice did develop fibrosis once their blood pressure had
been increased. Hypertension is a factor that has not yet
been investigated in other organs and may be a contribu-
ting factor in the development of organ fibrosis.
C57BL/6 and BALB/c mice were used to study suscep-
tibility to CKD by inducing fibrosis through ureteralobstruction by clamping of the ureters. C57BL/6 mice
showed pronounced inflammation and a development
towards fibrosis, whereas BALB/c mice showed a re-
duced response, with damaged renal tissue returning to
normal after injury [26]. This is in contradiction to the
patterns shown in the liver where BALB/c mice were
susceptible to fibrosis, but follows similar results in the
lung. Zeisberg and colleagues induced renal injury by
administration of rhBMP-7 via IP injection, MRL/MpJ, and
MRL/MpJlpr/lpr mice were used to assess strain differences
[32]. MRL/MpJlpr/lpr mice were shown to be susceptible
whereas the MRL/MpJ mice were shown to be resistant to
renal fibrosis post-injection. MRL/MpJ mice have a regen-
erative capacity to heal ear-hole punches completely and
rapidly without scarring [76]. It would be interesting to
determine how this strain would respond in response to
injuries that have been described in other organs to de-
termine whether regenerative capacity is linked to the fi-
brotic response.
Another study assessed the susceptibility of four mouse
strains: C57BL/6 and 129/Sv and F1 and F2 crosses of
C57BL/6 and 129/Sv. Mice were uninephrectomised and
hypertension was induced. 129/Sv mice demonstrated in-
creased blood pressure, glomerulosclerosis and interstitial
fibrosis in comparison to C57BL/6 mice. F1 and F2 crosses
showed an intermediate response [77]. There have been
limited studies to assess strain susceptibility to kidney fi-
brosis. More studies are necessary to develop the under-
standing of which strains are susceptible and resistant to
find potential QTLs and candidate genes that can be re-
lated back to the human condition of kidney fibrosis.
Mouse strain differences in susceptibility to
intestinal fibrosis
Intestinal fibrosis is a complication associated with in-
flammatory bowel disease (IBD) and is associated with
both Crohn’s disease and ulcerative colitis. Crohn’s dis-
ease can affect the entire thickness of the intestinal wall
and normally requires surgery as a management therapy.
Acute injury of the intestinal mucosa is followed by a
process of normal wound healing to restore tissue func-
tion. Deposition of excess ECM causes thickening of the
mucosa and narrowing of the lumen, leading to obstruc-
tion of the bowel [78].
In mouse models, intestinal fibrosis has been induced by
either a single dose of radiation to the colorectum with set
or varying lengths of tissue exposed or by worm parasite-
induced or intra- rectal administration of trinitrobenzene
sulfonic acid [79]. Then, the fibrotic response is measured
after 6 weeks. Using the search terms described, three
studies fitted the criteria with irradiation used in two stu-
dies and treatment with the worm Trichuris muris (T.
muris) used in one study. There was evidence to suggest
that mouse strains were either susceptible or resistant to
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fibrosis-susceptible whereas C3Hf/Kam mice were resist-
ant to irradiation-induced fibrosis [23]. However as with
the pulmonary fibrosis studies, the dose of radiation was
the same but the lengths of tissue that were exposed to ra-
diation varied, and this is likely to affect the extent of
fibrosis.
Where the colon was irradiated once, C57Bl/6 mice
showed greater bowel obstruction from day 60 in compari-
son to C3Hf/Kam mice. There was a threshold in the
length of colorectum that was irradiated before obstruction
was demonstrated, a threshold that was greater in the C3H
mice [23]. The same group later repeated this study but
examined obstruction between 6 hours and 120 days as
opposed to the previous study [24]. C57BL/6 mice showed
increased evidence of hyperplastic crypts and fibrosis in
the intestinal mucosa in comparison to the C3H mice.
Fibrosis was seen in the C57BL/6 strain at 75 days, which
was much earlier than in the C3H mice. Significant strain-
dependent differences were seen in the architecture of the
colon between the strains but not in the levels of TGF-β1,
2, 3 or TNF-α [24]. These results support the findings
demonstrated in models of pulmonary fibrosis due to ir-
radiation. It is also apparent that particular doses may be
harmless but once a dosage threshold has been reached,
this may be detrimental to particular strains.
A recent study assessed two strains of mice, a suscep-
tible AKR/OlaHsd and a resistant BALB/cOlaHsd and
their F1 offspring after treatment with T.muris for
35 days to assess potential QTLs. They identified seven
potential QTL and four candidate genes for susceptibil-
ity to colitis, FCgR1, Ptpn22, RoRc and Vav3 [80]. How-
ever, these data have not yet been mapped to the human
condition of intestinal fibrosis.
Mouse strain differences in susceptibility to cardiac fibrosis
Cardiac fibrosis is a known causative factor of cardiac
failure. Injury to the heart may be caused by insults
that result in a significant loss of cardiomyocytes such
as myocardial infarction or do not lead to extensive
cardiomyocyte loss, such as pressure overload, hy-
pertrophic cardiomyopathy, dilated cardiomyopathy,
repetitive ischaemic episodes, and diabetes or obesity-
induced cardiomyopathy [81]. Resulting fibrosis with
excessive accumulation of ECM proteins in the heart
causes increased mechanical stiffness and disruption to
electrical impulses that control the contraction of the
heart and leads to an increased chance of arrhythmias.
After myocardial infarction, normal cardiac tissue heals by
forming a scar rather than regenerating new tissue. Car-
diac fibroblasts play a key role in the scarring process,
and, due to their different sources in the heart, they are a
highly heterogenic cell population. It is proposed that car-
diac fibroblasts can derive either from resident fibroblasts;from endothelial cells via an endothelial-mesenchymal
transition; or from bone marrow-derived circulating pro-
genitor cells, monocytes and fibrocytes [82,83].
Cardiac fibrosis in animal models can be induced by a
physical injury such as cryogenic damage or by coronary
artery ligation to produce myocardial infarction. Using
the search terms described, five studies fitted the criteria
with two inducing infarct and three using a physical
injury to induce fibrosis. As with the other types of or-
gans, certain mouse strains were either susceptible or re-
sistant to cardiac fibrosis but as with the other fibrosis
studies, the route of injury was found to vary and is likely
to have had an impact on the extent of the fibrosis.
In one particular study, five strains of mice were
subjected to coronary artery ligation and myocardial
infarction assessed up to 28 days post-injury [84]. Infarct
rupture occurred between 3 and 6 days and was most
frequent in 129S6 mice (62%), then by C57BL/6 (36%),
FVB (29%), Swiss (23%) and lastly BALB/c (5%). Further-
more, 129S6 and C57BL/6 mice were shown to be fibrosis-
susceptible whereas BALB/c mice were fibrosis-resistant
but showed significant secondary thinning of the infarct
area [84]. A strain of mouse, MRL/MpJ, which was also
used in renal fibrosis studies, was found to have the cap-
acity to regenerate cardiac tissue with normal function
60 days after a single myocardial infarction caused by cryo-
genic damage to the right ventricle. Scarring and cardiac fi-
brosis was markedly reduced in comparison with C57BL/6
mice [33]. However, contradictory findings were later pro-
duced by several other groups using both cryoinjury [34]
and coronary artery ligation procedures [85].
These studies showed that both MRL/MpJ and C57BL/6
mice repaired damaged tissue with pronounced scar-
ring after infarction with no significant difference seen
between the two strains. The reason for this difference
in findings remains unexplained given that there was
no major discrepancy in the experimental protocols
used. Faulx and colleagues used a different model of
cardiac fibrosis involving administering six daily in-
jections of the catecholamine, isoproterenol, which
causes left ventricular hypertrophy independent of
blood pressure [29]. Excessive deposition of ECM pro-
teins was linked to the development of hypertension
and myocardial infarction. A/J mice showed a greater
hypertrophic response in comparison to C57BL/6J
mice, which displayed greater levels of myocardial
metabolic enzymes that may protect against the devel-
opment of fibrosis [29].
Similarly to the other types of organ fibrosis, few studies
have assessed strain susceptibility to cardiac fibrosis. Once
again, more studies are necessary to identify potential can-
didate genes to develop a better understanding of the hu-
man clinical condition and to identify individuals that are
susceptible to cardiac fibrosis.
Table 2 Regeneration and strain susceptibility
Wound type Strain Resistance Reference
Skin MRL/MPJ Fast Healer [93]




Digit tip Amputation MRL More regrowth [5,92]
C57BL/6 Reduced regrowth
DBA/2 Reduced regrowth
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This systematic review has shown that there are differ-
ences in susceptibility to develop fibrosis in various in-
bred mouse strains. These differences are also organ
specific. It is possible that different types of injury used
to induce fibrosis in each organ may be linked to differ-
ent signaling pathways, which themselves may be linked
to susceptibility. However, only a limited number of
studies have included the same strains of mice or same
type of injury, which would allow a thorough com-
parison of the development of fibrosis in different organ
systems. From the studies analysed, there are many
strains that were assessed only in relation to one type of
organ pathology, with C57BL/6 being the most com-
monly used. It is therefore difficult to directly compare
the organ responses or route of injury in multiple strains
in relation to susceptibility to the development of fibro-
sis. The possible mechanisms involved in susceptibility
and protection from fibrosis are complex as there are
many highly interactive pathways involved. In part, some
of the findings may relate to the ability to process and
clear the injurious agent. For instance, high levels of bleo-
mycin hydrolase have been found in mice that are ‘non-fi-
brotic’ after bleomycin-induced damage in the lung [7].
A study that was performed in humans showed that
variation in the bleomycin hydrolase gene is associated
with reduced survival after treatment with chemotherapy
in patients with testicular germ cell cancer [86]. Future
studies that assess potential QTLs while using different
strains of mice may help to determine which patients
undergoing chemotherapy may be susceptible to lung fi-
brosis. It is possible that a different profile of key factors,
both at baseline and involved in the repair process, may
be mouse strain-determined and dictate susceptibility or
resistance to fibrosis. In hepatic fibrosis, the level of IL-4,
which is responsible for promoting collagen synthesis, were
higher in the susceptible mice than in the mice that were
resistant [21]. Also, in the liver, production of hyalu-
ronan was associated with the deposition of ECM, and
levels of hyaluronan synthase 2, which catalyses the syn-
thesis of hyaluronan, could be another potential factor
determining mouse strain differences [20]. Our group
investigated mouse strain differences in relation to sus-
ceptibility to peritoneal fibrosis using an intraperitoneal
injection of adenovirus over expressing TGF-β1 [87]. The
fibrotic response was graded between mouse strains with
C57BL/6J mice showing a significant fibrogenic response
and SJL/J mice being resistant. Both the DBA/2 and C3H/
HeJ mice demonstrated an intermediate response. A pos-
sible reason for the strain difference in response may be
linked to mesothelial layer integrity and, hence, suscepti-
bility to EMT leading to fibrosis and delayed epithelial re-
pair in C57BL/6J. Currently there have been no other
investigations into the mechanisms of the strain differencein susceptibility to peritoneal fibrosis. Further assessments
are necessary to determine the mechanisms and candidate
genes responsible.
Mouse models provide a controlled environment to study
the effects of alleles that have been identified as risk alleles
in the clinic. Phenotypes measured in varying strains can
act as a base for genetic studies to determine the variation
that causes a specific phenotype to develop and predisposes
an individual to a disease, in this case fibrosis. These mouse
studies are complimentary to human association studies
and allow the analysis firstly of the clinical disease but also
of the genetic variants that are associated with the disease
to be assessed in a controlled environment [88].
Organs in the same inbred strain of mouse share the
same DNA sequence, yet exhibit widely differing struc-
ture and function, demonstrating major epigenetic con-
trol of gene expression in normal development and
physiology. The observation that there are different
susceptibilities of various organs to fibrosis within the
same mouse strain also highlights epigenetic control as
an important modulator of fibrotic response. Evidence
that differential DNA methylation of genes in an organ
within a strain (the organ methylome) controls sus-
ceptibility or resistance of that organ to fibrotic injury,
is a recent and new hypothesis, which requires further
examination. Already, experimental data has been pre-
sented that the fibrotic response is in part under epi-
genetic control in the kidney [89].
Tissue regeneration, like fibrosis, has also been linked to
the genetic background of mouse strains (Table 2). In par-
ticular, one strain of mouse was able to fully regenerate in-
jured tissue without scarring. One study compared two
strains of mice - MRL/MpJ-Fas (MRL-F) and C57BL/6 -
and found that MRL-F mice completely heal a hole
punched into the ear within 4 weeks with complete restor-
ation of tissue function in comparison to C57BL/6 mice,
which healed only 30% of the lesion and produced scar tis-
sue [90]. When studying the mice, three stages of the
healing process were described: the initiation stage, the fast
healing stage and the slow healing stage. At the fast healing
stage, there was dramatic variation between strains, with
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6 mice. Later studies showed a correlation between the
breakdown of basement membrane proteins, inflammatory
response and increased protease/anti-proteases with ear-
hole closure [91]. Similar studies using MRL/MPJ, C57BL/
6 and BALB/c mice found that all strains healed similarly
in the first 3 days and all mice, except the MRL/MPJ,
showed an increase in the wound area up to 2 weeks after
initial wounding possibly due to increased tissue necrosis.
Regeneration of amputated digit tips was also investigated
in MRL mice, and digits were found to re-grow with partial
reformation of nails significantly more than the other
strains, C57BL/6 and DBA/2 mice [92].
Conclusion
This review discusses the increasing evidence that gen-
etic susceptibility plays a role in regulating the develop-
ment of fibrosis and also in regeneration in various
tissues and organs. Various strains of mice respond dif-
ferently to fibrosis induced by different agents but inter-
estingly in varying organs. The possibility that there may
be organ specific responses that vary between different
strains of mice highlights the complex interaction be-
tween the genome and epigenome. More studies need to
be performed with standard experimental procedures
using the same inbred mouse strains to identify true
genetic control of susceptibility and resistance to the
stimulus. Then, within a strain, relating organ suscepti-
bility or resistance to the epigenome of that organ
(methylome), histone lysine code and miRNA signature
may explain the mechanisms and pathways responsible
for the fibrotic or non-fibrotic phenotypes that are ob-
served in the various strains. Better understanding of the
interaction between the genome and organ epigenome
in the mouse will produce a powerful tool to unpick
complex but similar mechanisms of fibrosis in man.
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